Syed Ibrahim Bukhari: From Conventional Therapy to Gene-Based Approaches in Hemophilia Care
Syed Ibrahim Bukhari, Clinical Fellow at The Hospital for Sick Children, shared a post on LinkedIn:
“In honor of World Hemophilia Day 2025, I had the privilege of presenting on ‘Hemophilia Management: Current Standards and Emerging Frontiers’ at the National Institute of Child Health (NICH) in Karachi.
The session focused on the critical importance of specialized care for pediatric patients and the evolving landscape of treatment.
Key Highlights from the Presentation:
The Core Challenge: Hemophilia A and B are X-linked recessive disorders characterized by deficiencies in clotting factors VIII and IX, respectively, leading to prolonged bleeding and potential joint damage.
Diagnosis and Severity: We discussed the importance of classifying severity based on factor levels—Severe (<1 percent), Moderate (1-5 percent), and Mild (5-40 percent)—to tailor treatment effectively.
Management Pillars: The talk emphasized the ‘P.R.I.C.E’ protocol for acute bleeds (Protection, Rest, Ice, Compression, Elevation) alongside prompt factor replacement therapy.
Prophylaxis versus Episodic Care: A major focus was the shift toward prophylaxis (regular treatment to prevent bleeds) as the gold standard for preventing chronic hemophilic arthropathy and improving quality of life.
Inhibitors and Complications: We addressed the challenge of inhibitors, where the body’s immune system reacts against replacement factors, necessitating advanced bypass agents or immune tolerance induction.
Future Frontiers: I shared insights into the potential of gene therapy and non-factor replacement therapies, like Emicizumab, which are revolutionizing how we approach long-term care.
Thank you to the team at NICH for organizing this event and for their unwavering commitment to our young patients in Karachi.
Together, we can strive for a future where ‘Access for All’ becomes a reality.”
See more in the gallery.
Stay updated with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy